Wheatland Advisors Inc. Has $2.38 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Wheatland Advisors Inc. lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.7% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 35,160 shares of the biopharmaceutical company’s stock after selling 600 shares during the quarter. Gilead Sciences comprises about 1.8% of Wheatland Advisors Inc.’s portfolio, making the stock its 18th largest holding. Wheatland Advisors Inc.’s holdings in Gilead Sciences were worth $2,375,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Parnassus Investments CA raised its stake in Gilead Sciences by 21.2% in the 1st quarter. Parnassus Investments CA now owns 13,074,555 shares of the biopharmaceutical company’s stock worth $849,976,000 after purchasing an additional 2,288,767 shares in the last quarter. Sanders Capital LLC raised its stake in Gilead Sciences by 2.1% in the 2nd quarter. Sanders Capital LLC now owns 11,526,033 shares of the biopharmaceutical company’s stock worth $842,146,000 after purchasing an additional 234,100 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in Gilead Sciences by 3.3% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 5,213,760 shares of the biopharmaceutical company’s stock worth $338,947,000 after purchasing an additional 167,292 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Gilead Sciences by 1.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 5,129,197 shares of the biopharmaceutical company’s stock worth $320,822,000 after purchasing an additional 51,905 shares in the last quarter. Finally, LSV Asset Management increased its holdings in Gilead Sciences by 0.8% in the 1st quarter. LSV Asset Management now owns 4,686,501 shares of the biopharmaceutical company’s stock valued at $304,669,000 after buying an additional 37,464 shares during the period. Institutional investors own 78.78% of the company’s stock.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 7,200 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total transaction of $468,504.00. Following the sale, the executive vice president now directly owns 34,398 shares of the company’s stock, valued at approximately $2,238,277.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Brett A. Pletcher sold 608 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $64.35, for a total transaction of $39,124.80. Following the sale, the executive vice president now directly owns 27,198 shares in the company, valued at $1,750,191.30. The disclosure for this sale can be found here. Insiders have sold a total of 13,624 shares of company stock worth $907,479 over the last ninety days. 0.20% of the stock is currently owned by insiders.

Shares of Gilead Sciences stock traded down $1.71 during midday trading on Friday, hitting $62.51. 5,445,326 shares of the company traded hands, compared to its average volume of 6,143,986. The stock has a market cap of $81.33 billion, a price-to-earnings ratio of 10.16, a PEG ratio of 3.05 and a beta of 1.16. The company has a debt-to-equity ratio of 1.13, a quick ratio of 3.67 and a current ratio of 3.76. The firm’s fifty day moving average price is $65.54 and its 200-day moving average price is $65.74. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $79.61.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.14. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.54 billion. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The firm’s revenue was down 2.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.91 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 6.65 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.03%. The ex-dividend date of this dividend is Thursday, September 12th. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.

Several research firms have commented on GILD. Evercore ISI reissued a “buy” rating on shares of Gilead Sciences in a report on Friday, May 17th. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a report on Monday, July 15th. Raymond James raised their target price on shares of Gilead Sciences from $83.00 to $86.00 and gave the company a “strong-buy” rating in a report on Wednesday, July 31st. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, JPMorgan Chase & Co. reissued a “buy” rating and issued a $85.00 target price on shares of Gilead Sciences in a report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $82.29.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: How do CD ladders protect against rising interest rates?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.